Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $60.00

Sanofi (NASDAQ:SNY) has been assigned a consensus recommendation of “Buy” from the five brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $62.50.

SNY has been the topic of several research reports. The Goldman Sachs Group began coverage on shares of Sanofi in a report on Friday. They set a “neutral” rating and a $65.00 price objective on the stock. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th.

Institutional Trading of Sanofi

Several institutional investors and hedge funds have recently made changes to their positions in the company. Abel Hall LLC grew its position in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after purchasing an additional 194 shares in the last quarter. Providence Capital Advisors LLC boosted its stake in shares of Sanofi by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock worth $2,653,000 after buying an additional 201 shares during the last quarter. Keudell Morrison Wealth Management grew its holdings in shares of Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after acquiring an additional 217 shares in the last quarter. Bailard Inc. increased its position in shares of Sanofi by 1.4% during the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock valued at $789,000 after acquiring an additional 220 shares during the last quarter. Finally, Old Port Advisors lifted its holdings in Sanofi by 0.6% during the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock worth $1,770,000 after acquiring an additional 232 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $56.90 on Friday. The business has a 50-day simple moving average of $54.55 and a 200 day simple moving average of $52.85. Sanofi has a one year low of $45.22 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market capitalization of $144.40 billion, a price-to-earnings ratio of 22.85, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.